– GUERNSEY, St. Peter Port – Syncona Ltd (LON: SYNC), a leading healthcare company focused on founding, building and funding a portfolio of global leaders in life sciences, today announced the appointment of Virginia Holmes to its Board as a Non-Executive Director effective on 1st January 2021.
“We are pleased to strengthen our Board of Directors with the appointment of Virginia. She has extensive experience and a proven track record of working with investment businesses as they look to develop and expand. Her expertise will be invaluable as we look to manage and grow a sustainable portfolio of leading life science companies.” said Board Chair, Melanie Gee.
About Virginia Holmes
Virginia has extensive knowledge of the financial services industry including investment management and banking. She was previously Chief Executive of AXA Investment Managers UK and held several senior leadership roles over more than a decade at Barclays Bank Group.
Virginia also brings a wide range of Board experience, both with UK listed companies and organisations across various jurisdictions. She is currently a Non-Executive Director of Intermediate Capital Group plc, an FTSE 100 specialist asset manager, and of the European Opportunities Trust plc, a closed-ended European equity fund. She is also Chair of USS Investment Management Ltd, the fiduciary manager of Universities Superannuation Scheme Ltd.
Virginia Holmes commented: “I am very much looking forward to joining Syncona’s Board and working with their expert life science investment team, to support them in accelerating the growth of the business and delivering the purpose to invest to extend and enhance human life.”
Syncona is a healthcare company focused on founding, building and funding a portfolio of global leaders in life science. Our purpose is to invest to extend and enhance human life. We do this by founding and building companies to deliver transformational treatments to patients in areas of high unmet need.
Our strategy is to found, build and fund companies around exceptional science to create a dynamic portfolio of 15-20 globally leading healthcare businesses for the benefit of all our stakeholders. We focus on developing treatments for patients by working in close partnership with world-class academic founders and management teams. Our strategic balance sheet underpins our strategy enabling us to take a long-term view as we look to improve the lives of patients with no or few treatment options, build sustainable life science companies and deliver strong risk-adjusted returns to shareholders.
For more information: https://www.synconaltd.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.